Centessa Pharmaceuticals plc held its 2025 Annual General Meeting on June 20, 2025. All proposals submitted to a vote were approved. Arjun Goyal, M.D., M.Phil., M.B.A., and Samarth Kulkarni, Ph.D., were re-appointed as directors. KPMG LLP was re-appointed as the U.K. statutory auditors. The Board of Directors was empowered to allot equity securities for cash. Additionally, the directors were authorized to allot shares or grant rights to subscribe for or convert securities into shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.